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Edited by Lukas HuberAbstract Transmissible spongiform encephalopathies (TSEs)
are neurodegenerative disorders aﬀecting humans and animals.
At present, it is not possible to recognize individuals incubating
the disease before the clinical symptoms appear. We investigated
the eﬀectiveness of the ‘‘Protein Misfolding Cyclic Ampliﬁca-
tion’’ (PMCA) technology to detect the protease-resistance dis-
ease-associated prion protein (PrPres) in pre-symptomatic stages.
PMCA allowed detection of PrPres in the brain of pre-symptom-
atic hamsters, enabling a clear identiﬁcation of infected animals
as early as two weeks after inoculation. Furthermore, PMCA
was able to amplify minute quantities of PrPres from a variety
of experimental and natural TSEs. Finally, PMCA allowed
the demonstration of PrPres in an experimentally infected cow
32 month post-inoculation, that did not show clinical signs and
was negative by standard Western blot analysis. Our ﬁndings
indicate that PMCA may be useful for the development of an ul-
tra-sensitive diagnostic test to minimize the risk of further prop-
agation of TSEs.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Although transmissible spongiform encephalopathies (TSEs)
are relatively rare in humans, the recent appearance of a new
clinicopathologic phenotype, termed variant CJD (vCJD),
and the experimental evidence that this phenotype is causally
linked to the bovine spongiform encephalopathy (BSE) agent
[1,2] have raised concern about a possible outbreak of a large
epidemic in human population [3]. Over the past few years, it
has become clear that BSE is a serious problem, and despite
the imposition of stringent precautionary measures the disease
continues to expand in some European countries and has been*Corresponding author. Fax: +1 409 747 0020.
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doi:10.1016/j.febslet.2004.12.035recently reported in North America and Japan, where it has
produced serious economic damage to the veterinary industry.
The problem is aggravated by the lack of a reliable way to
identify cattle incubating the disease during the long and silent
period from the time of infection to the appearance of clinical
signs [4,5]. Although several tests have been developed to diag-
nose BSE in postmortem brain tissue, their usefulness to detect
pre-symptomatic cases has not been reported, except for one of
the tests in animals in stages close to the clinical phase [6].
Based on estimations of PrPres levels during the incubation
period, it seems unlikely that the current analytical methods
can identify cattle at early phases of disease [4,5]. Thus, it is
possible that infected animals without clinical signs and nega-
tive to the available biochemical tests can enter into the food
chain, imposing a serious risk to human health. Pre-symptom-
atic detection of CJD in living patients is not possible either
[1,5]. In a potential scenario where a substantial number of
people may be incubating vCJD, the lack of a pre-symptom-
atic test has raised the fear of iatrogenic propagation of the
disease [5,7]. A pre-symptomatic diagnosis is also very impor-
tant for treatment perspectives, as therapeutic intervention
should start in an early stage, before the appearance of clinical
signs and the occurrence of irreversible brain changes. Accord-
ingly, the development of tests that can eﬀectively recognize
humans and animals incubating TSE is a top priority [4,5].
The central event in the disease pathogenesis is the forma-
tion of a misfolded protease-resistant protein named PrPres,
which is a post-translationally modiﬁed version of a normal
protein, termed PrPC [8]. In the present article, we study the
application of the Protein Misfolding Cyclic Ampliﬁcation
(PMCA) technology for pre-symptomatic detection of PrPres
in the brain of scrapie-infected hamsters and BSE-infected
cow, as well as the adaptation of PMCA [9] to detect small
quantities of PrPres from diﬀerent species, including mice,
sheep, goat, cattle and humans with sporadic CJD (sCJD)
and vCJD. The PMCA technology was experimentally de-
signed to mimic some of the fundamental steps involved in
PrPres replication in vivo at an accelerated kinetic [10]. In a
cyclic manner, conceptually analogous to PCR cycling, a min-
ute quantity of PrPres is incubated with excess PrPC to enlarge
the PrPres aggregates that are then sonicated to generateblished by Elsevier B.V. All rights reserved.
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PrPres [9]. A modest level of ampliﬁcation has also been ob-
served without sonication [9,11], and the extent of conversion
depends upon the number of PMCA cycles [9,12] and can be
enhanced by small RNA fragments [13].2. Materials and methods
2.1. Infection of hamsters with scrapie
Golden Syrian hamsters were injected intra-cerebrally either with 25
ll of 1% brain homogenate prepared from 263 K scrapie-infected ham-
sters in the terminal stage of disease (n = 40) or with vehicle solution
(n = 40). The animals exposed to the infectious agent developed clinical
signs of disease about 10 weeks after inoculation. Symptoms included
hyper-reactivity to acoustic stimulation, aggressive behavior and
impairment of motor skills. Starting from day 14 post-inoculation,
four animals per group were sacriﬁced every week; the brain was re-
moved and immediately frozen at 80 C until analyzed.
2.2. Experimental infection of cows with BSE
These samples were kindly provided by the Veterinary Laboratory
Agency (New Haw, Addlestone, Surrey, UK). Cattle 4–6 months of
age were challenged orally with 100 g of BSE brain homogenate by syr-
inge on the base of the tongue at the entrance of the pharynx. The
inoculum was prepared from a pool of brain stems from conﬁrmed
ﬁeld cases of BSE. Clinical signs were assessed monthly by veterinarian
experts from the Veterinary Laboratory Agency (VLA, New Haw.
Addlestone, Surrey, UK). Animals were culled at 32 month post-
inoculation and samples from encephalic area were immediately taken,
frozen and kept at 80 C.
2.3. Brain tissue from other TSEs
In addition to experimental hamster scrapie and BSE, brain tissue
samples from individuals with histopathologically conﬁrmed disease
were used for the study. The material used came from mice infected
with the RML strain of scrapie, sheeps and goats with natural scrapie,
a patient with vCJD and patients with sCJD having type 1 and type 2
PrPres [14]. In all the cases, the postmortem delay was <6 h and tissue
was kept frozen at 80 C until use.
2.4. Brain tissue from healthy individuals
As substrate for conversion, we used brains from healthy individuals
of the same species. For experimental rodents (mice and hamsters),
animals were perfused with phosphate buﬀered saline (PBS) containing
5 mM EDTA previously to sacriﬁce in order to remove as much blood
as possible from the brain. Postmortem delay for healthy brains from
cattle, sheep, goat and human was <2 h. Tissue was stored frozen at
80 C until homogenization.
2.5. Preparation of brain homogenates
Five and ten percent brain homogenates (w/v) were prepared in
conversion buﬀer (phosphate-buﬀered saline containing 0.5% Triton
X-100, 0.05% sodium dodecyl sulfate and the Completee cocktail of
protease inhibitors from Boehringer Mannheim). The samples were
clariﬁed by a brief, low-speed centrifugation (1500 rpm for 10 s) using
an Eppendorf centrifuge (model 5414). Dilutions are always expressed
in relation to the brain, for example a 100-fold dilution is equivalent to
a 1% brain homogenate.
2.6. PMCA procedure
For pre-symptomatic detection of PrPres in experimental animals, 60
ll aliquots of 5% brain homogenates were either frozen immediately
after homogenization or subjected to 20 PMCA cycles, where the sam-
ples were incubated at 37 C with agitation and subjected to sonication
every hour (5 pulses of 0.1 s at 0.9 s interval) using a microsonicator
(Bandelin Electronic, model Sonopuls) at a power setting of 40% (28
W/pulse) for hamster and 10% for cattle. For the experiment using
pre-symptomatic hamster brain, no additional substrate (healthy brain
homogenate) was added, because the aim was to use the PrPC present
in these samples for conversion. For ampliﬁcation of PrPres from sam-ples of symptomatic subjects of diﬀerent species (hamster, mouse,
sheep, goat, cattle and human), aliquots of TSE-brain homogenates
were diluted into 5% (cattle and human) or 10% (hamster, mouse,
sheep and goat) normal brain homogenate from the same species, pre-
pared in the conversion buﬀer. The ﬁnal dilution of TSE-homogenate
was 1600 for hamster, 500 for mouse and human, 200 for sheep and
goat, and 150 for cattle, and the ﬁnal reaction volume was 60 ll for
all samples. Samples were either frozen immediately at 80 C or sub-
jected to 5 (human material) or 10 (hamster, mouse, sheep, goat and
cattle) PMCA cycles. The power of the sonicator was set at 30% for
human samples, 20% for sheep and goat, and 10% for mouse and
cattle.
2.7. PrPres detection
Following ampliﬁcation, the samples were digested with proteinase
K (PK) at 37 C for 1 h and the reaction was stopped with 5 mM phen-
ylmethylsulfonylﬂuoride. The PK concentration was as follows: 100
lg/ml for hamster, 50 lg/ml for human samples, 25 lg/ml for sheep,
goat, mouse and cattle. PrPres was detected by Western blotting as de-
scribed before [9] using the following anti-PrP antibodies: 3F4 (dilution
1:50 000) for human and hamster samples, 6H4 (dilution 1:5000) for
mouse and cattle, and 4B4 (1:2000) for sheep and goat. The immuno-
reactive bands were quantiﬁed by densitometry using the program Sig-
maGel version 1.0 (Jandel Scientiﬁc).3. Results
To investigate the potential of PMCA for pre-symptomatic
detection of prion disease, Syrian hamsters were inoculated in-
tra-cerebrally with the 263 K strain of scrapie and analyzed at
diﬀerent stages during the preclinical phase. Infected and con-
trol animals were sacriﬁced every week (n = 4/group) and 5%
brain homogenates were subjected to 20 ampliﬁcation cycles.
In these experiments, normal brain homogenate was not added
to the reaction mixture, because endogenous PrPC was used as
a substrate for the conversion. At each time point after inocu-
lation, the PrPres signal was signiﬁcantly higher in the homog-
enates subjected to PMCA than in the corresponding
untreated samples (Fig. 1). At times when the initial quantity
of PrPres is high, new formation of misfolded protein is very
low, because in these samples PrPC substrate becomes a limit-
ing factor. Strikingly, PMCA allowed detection of abnormal
PrP even at the earliest time in which hamsters were sacriﬁced
(two weeks after inoculation), long before they showed any
clinical sign of the disease (Fig. 1). By contrast, without cyclic
ampliﬁcation, PrPres was unequivocally demonstrable in the
brain of scrapie-infected hamsters six weeks after inoculation,
only four weeks before the appearance of clinical signs. PrPres
was not detected in any of the uninfected control animals, with
or without PMCA (data not shown).
We then analyzed the suitability of this technique for ampli-
ﬁcation of biochemically distinct types of PrPres from diﬀerent
species with TSEs, including hamsters and mice with experi-
mental scrapie, sheep and goat with natural scrapie, cattle with
natural BSE (Fig. 2) and humans with sCJD and vCJD
(Fig. 3). TSEs-brain homogenates were diluted into a freshly
prepared normal brain homogenate from the same species.
Samples were either frozen immediately after mixing or sub-
jected to PMCA cycles under conditions described in Section
2. The study showed that PMCA was able to amplify PrPres
in all instances, although the experimental setting needed for
optimal results was dependent upon PrPres type and animal
species. A critical factor was the ultrasound strength used for
ampliﬁcation, suggesting dissimilar conformation and/or
aggregation states of disease-speciﬁc PrPres isoforms. The
Fig. 1. Pre-symptomatic detection of PrPres in experimental hamster
scrapie. Western blot analysis of brain homogenates from hamsters
that were sacriﬁced at diﬀerent times after infection with the 263 K
strain of scrapie. Samples before and after PMCA (20 cycles with
sonication power of 28 W/pulse) were subjected to PK digestion (100
lg/ml for 1 h at 37 C) and probed with the antibody 3F4 (1:50 000).
The upper panel shows representative blots of those obtained with four
diﬀerent animals per group. The intensity of PrP-immunoreactive
bands was evaluated by densitometry. Results of densitometric
analysis are reported in the lower panel, where each bar represents
the average of samples from four animals. Statistical analysis by two
ways ANOVA showed that the eﬀect of PMCA on PrPres detection was
highly signiﬁcant (P < 0.0001).
Fig. 3. Cyclic ampliﬁcation of PrPres from sporadic and vCJD. Brain
homogenates from two patients with sCJD having type 1 and type 2
PrPres, respectively, and one patient with vCJD were added to normal
human brain homogenate (Met/Met genotype) at a ﬁnal dilution of
1:500. After ﬁve ampliﬁcation cycles with a sonication power set at 21
W/pulse, the samples were digested with PK (50 lg/ml for 1 h at 37 C)
and analyzed by Western blot. The upper band of sCJD samples
(labeled with an asterisk) on the basis of the molecular weight likely
represents PrPres dimers. Each blot is representative of at least three
independent experiments done with diﬀerent samples. Estimations by
densitometric analysis indicate that the ampliﬁcation rate was 3.5, 4
and 10-folds for the samples of sCJD type I, sCJD type II and vCJD,
respectively.
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by densitometric analysis of the blots and varied among spe-
cies (see legends Figs. 2 and 3). The rate of ampliﬁcation de-
pends on the conditions used and the number of cycles
carried out. The purpose of this study was not to analyze the
maximum ampliﬁcation factor for each sample, but rather to
show that the technology can be adapted to diverse PrPres
sources. After PMCA, it was common to observe extra-bands
with a molecular weight higher than PrPres, likely correspond-
ing to PrP aggregates or to residual full-length PrP due toFig. 2. Cyclic ampliﬁcation of PrPres from diﬀerent mammals with experime
experimental scrapie, sheep and goat with natural scrapie and cattle with natu
to get ﬁnal dilutions of 1:1600, 1:500, 1:200, 1:200 and 1:150, respectively.
without ampliﬁcation. Ten ampliﬁcation cycles were carried out on all sample
and cattle) W/pulse. After PK digestion, using the conditions described in Se
kDa) labeled with an asterisk that was present in most samples (particul
representative of at least three independent experiments done with diﬀerent s
8, 7 and 32 for the samples showed in the ﬁgure from hamster, mice, sheep,incomplete PK digestion (Fig. 3, asterisks). This technical
problem could be minimized by the addition of more detergent
(up to 0.2% SDS, ﬁnal concentration) or by increasing the tem-
perature of PK treatment to 45 C. Noteworthy, in sCJD sam-
ples, the Western blot proﬁle characteristic of diﬀerent types of
PrPres, i.e., type 1 and type 2, was faithfully transmitted to the
normal protein that was converted into PrPres with the same
proﬁle (Fig. 3). This is especially intriguing, since the substrate
used for ampliﬁcation was the same (a Met homozygous
PrPC).
Finally, we tested the usefulness of PMCA for pre-symptom-
atic detection of PrPres in BSE. Experiments were carried out
using brain samples from a cow that was experimentally in-
fected 32 months earlier with BSE by oral route. At the time
of sacriﬁce, the animal did not show any clinical sign of disease
and, upon neuropathological examination, no TSE-related
changes such as spongiosis and gliosis were observed. Most
importantly, no PrPres was detectable by Western blot analysis.
However, when the samples were subjected to 20 PMCAntal or natural TSE. Brain homogenates from hamster and mice with
ral BSE were added to normal brain homogenate from the same species
These dilutions were chosen to obtain a weak signal on Western blot
s at a sonication power of 28 (hamster), 14 (sheep and goat) or 7 (mice
ction 2, PrPres was detected by Western blot. The upper band (40–50
arly after PMCA) likely corresponds to PrPres dimers. Each blot is
amples. Densitometric analysis revealed an ampliﬁcation rate of 40, 35,
goat and cattle, respectively.
Fig. 4. Pre-symptomatic detection of PrPres in experimental BSE. Brain homogenates from a cow that was experimentally infected with BSE by oral
route 32 months before were mixed with normal cattle brain homogenate. Samples were either frozen immediately (line 9) or subjected to 20 PMCA
cycles with a sonication power set at 7 W/pulse (line 10). For comparison, brain samples from three natural cases of BSE in the clinical phase of
disease were diluted 30-folds in normal brain and subjected to 0 (lines 1, 3 and 5) or 20 PMCA cycles (lines 2, 4 and 6). As negative control, a normal
cow brain homogenate was subjected to 0 (line 7) or 20 PMCA cycles (line 8). Cattle PrPres after PK treatment (25 lg/ml for 1 h at 37 C) and PrPC
before PK treatment were loaded in lines 11 and 12. The band labeled with an asterisk corresponds to incomplete digestion of di-glycosylated PrPC.
The experiment was repeated four times with similar results and a representative ﬁgure is shown.
C. Soto et al. / FEBS Letters 579 (2005) 638–642 641cycles, a strong immunoreactive signal consistent with PrPres
was present (Fig. 4). Lack of ampliﬁcation was observed when
normal cattle brain homogenate was subjected to PMCA in
the absence of BSE-infected material, but a consistently in-
creased signal after PMCA was observed for three diﬀerent
symptomatic cattle samples (Fig. 4). Here again, we observed
a PrP-immunoreactive band of higher molecular weight that
was particularly evident after PMCA and corresponded to resid-
ual PrPC from incomplete PK digestion (asterisks in Fig. 4).4. Discussion
At present, there is not validated analytical method for pre-
symptomatic diagnosis of non-genetic TSEs [5,15]. Currently,
the diagnosis is suspected on the basis of clinical examination
of symptomatic individuals [16] and is conﬁrmed postmortem
by neuropathological analysis and immunochemical detection
of PrPres in the central nervous system [15,16]. In some in-
stances (e.g., vCJD), pre-symptomatic detection of PrPres in
secondary lymphoid tissues such as the tonsils might be possi-
ble [17,18]. Furthermore, recent studies have shown that PrPres
is present consistently in the olfactory mucosa and frequently
in spleen and skeletal muscle of sCJD patients [19,20]. It would
be interesting to evaluate whether PMCA could be useful to in-
crease sensitivity of PrPres detection in tonsil, olfactory mucosa
or any other peripheral tissue or biological ﬂuid. A positive re-
sult in these experiments could lead to an early and sensitive
non-invasive biochemical diagnosis of CJD.
PrPres is the best-known biological marker for TSEs [5,8,15].
Accordingly, demonstration of PrPres in human or animal tis-
sues is central to TSE diagnosis. One important limitation to
this approach is the sensitivity of the detection system, since
amounts of PrPres high enough to be revealed by conventional
methods are only present in the brain at late stages of the dis-
ease. However, animal transmission studies show that infectiv-
ity is present at a relatively early stage of the incubation period
and gradually increases in quantity as the disease progresses
[21].
Our data indicate that PMCA is able to amplify undetect-
able quantities of PrPres from brain tissue of infected, but
not yet symptomatic hamsters and cattle, to an extent that is
easily revealed by Western blot. Pre-symptomatic detectionof PrPres in these samples might also be possible without
PMCA using methods more sensitive than Western blot or a
pre-concentration assay (e.g., with phosphotungstic acid pre-
cipitation [18,22]), as has been already showed with the Bio-
Rad sandwich ELISA test in pre-symptomatic BSE samples
[6]. However, PMCA oﬀers the unique advantage that it could
be used to boost the sensitivity of any detection method. The
longitudinal study on experimental hamster scrapie showed
that as early as two weeks after infection, i.e., at one ﬁfth of
the incubation time, it is possible to distinguish infected from
non-infected animals. As described earlier, the magnitude of
ampliﬁcation depends on the number of PMCA cycles [9].
Hence, the development of a quantitative PMCA, coupled
with a better understanding of the relationship between the
amount of PrPres and the state of the incubation period in a gi-
ven species, might allow estimating the time needed for a par-
ticular individual to develop clinical signs. The practical
application of PMCA for routine diagnosis will depend upon
having a system that can be automated and highthroughput.
We have recently reported the adaptation of the PMCA prin-
ciples to water bath sonicator that can be programmed for
automatic operation [23]. Using this technology, many more
ampliﬁcation cycles can be done routinely, which allowed to
dramatically increase the sensitivity of detection and to dem-
onstrate the infectious nature of in vitro generated PrPres (Cas-
tilla, J., Saa, P. and Soto, C., unpublished observations).
We also showed that PMCA can be applied successfully to a
variety of brain samples from experimental and natural TSEs of
humans and animals, including 263 K hamster scrapie, RML
mouse scrapie, sheep scrapie, goat scrapie, BSE and sporadic
and vCJD. Thus, the same principle operates with a number
of prion strains and all PrPres isoforms seem to be capable of
converting a large excess of PrPC in vitro under speciﬁc condi-
tions. Moreover, the Western blot proﬁle and the protease sen-
sitivity of newly formed PrPres are identical to those of PrPres
used for the reaction. The mechanism by which PrPres can faith-
fully transfer its biochemical properties to PrPC remains to be
elucidated. Interestingly, the ultrasound strength needed for
ampliﬁcation is diﬀerent for distinct animal species and PrPres
types. This is probably related to the particular conformation
and/or aggregation state of PrPres linked to each prion strain.
The latter has been hypothesized to explain the diﬀerences in bio-
logical properties (i.e., clinical features and neuropathological
642 C. Soto et al. / FEBS Letters 579 (2005) 638–642proﬁle of aﬀected individuals upon experimental transmission)
of diﬀerent strains of the prion agent [24–28]. We are currently
evaluating the eﬃciency of PrPres ampliﬁcation using cross spe-
cies combinations. Preliminary data indicate that the conver-
sion of PrPC induced by PrPres from a diﬀerent species is
much less eﬃcient and in some cases unachievable. These results
conﬁrm a previous report from Caugheys group using the cell-
free conversion system [29] and correlate well with species bar-
rier for prion propagation in vivo.
Access to pre-symptomatic samples from cattle or humans
known to be infected by prions is limited. However, based
on the observation that PMCA (i) enables detection of PrPres
in the brain of animals with experimental TSE at very early
phases of infection, and (ii) can be adapted to PrPres isoforms
associated with diﬀerent prion diseases including BSE and
CJD, it can be predicted that this technique may be useful
for pre-symptomatic detection of prions in the brain of cattle
and humans. This conclusion is supported by the proof-
of-concept experiment in which PrPres was easily detectable
by Western blot in the brain of a BSE-infected, pre-symptom-
atic cow after PMCA. Overall, our data may allow designing a
diagnostic test for humans and animals at an early stage of the
disease, and minimize the risk of further propagation of TSE
in humans.
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